tirzepatide how to say Pronounce pronounce tirzepatide Wacky Word Wednesday

Sources Eli Lilly, "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial" (May 21, 2026) TRIUMPH-1 topline: 28.3% at 80 weeks, 30.3% at 104 weeks, 45.3% achieving 30%+ weight loss ClinicalTrials.gov NCT05929066 (TRIUMPH-1) Phase 3, status Completed, primary completion April 6, 2026 Eli Lilly Q4 2025 earnings call transcript (February 4, 2026) confirmed regulatory submission planned for 2026 Eli Lilly press releases and investor communications ClinicalTrials.gov (TRIUMPH program trial registrations) Jastreboff AM, et al

GLP-1 receptors are present in two critical portions of this pathway: the ventral tegmental area and nucleus accumbens

In March 2022, the 2mg Ozempic dose was FDA-approved

Until full safety data are available, cautious patient selection and baseline risk assessment are advised

Clinical Research Findings on AOD-9604 In clinical trials involving approximately 900 participants across six human studies, AOD-9604 demonstrated a favorable safety and tolerability profile